RT Journal Article
T1 Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes
A1 Bogas, Gador
A1 Ariza, Adriana
A1 Vázquez-Revuelta, Paula
A1 Labella, Marina
A1 Madrigal-Burgaleta, R.
A1 Fernández-Santamaría, Rubén
A1 Calvo-Serrano, Silvia
A1 Villar-Chamorro, Esther
A1 Martín-Clavo, Susana
A1 Lebrón-Martín, Clara
A1 Mayorga Mayorga, Cristobalina
A1 Doña, Inmaculada
A1 Torres, María J.
K1 Cáncer - Quimioterapia
K1 Medicamentos - Ensayos
K1 Biomedicina
AB BackgroundDelabelling pathways offer confirmatory diagnosis and can prevent unnecessary second-line therapies or drug desensitization procedures after chemotherapeutic hypersensitivity reactions (CHT-HSRs). However, these pathways rely on risky in vivo tests. Data on whether in vitro tests could be helpful are scarce. We assessed the role of basophil activation test (BAT) in the diagnosis of HSRs to platin salts (PSs) and taxanes (TXs) in a well-defined population featuring varied endophenotypes and severities of HSRs.MethodsWe conducted a 3-year-long multicentric, prospective study with 121 suspected-immediate CHT-HSR patients. The allergy workup included clinical history (initial reaction based on Type I, cytokine release syndrome, and mixed phenotype's symptoms and if unable to fit in any of these, as “indeterminate”), skin testing (ST), and drug provocation testing (DPT), provided risk assessment was favorable. Final diagnosis classified patients as “hypersensitive,” “non-hypersensitive,” or “inconclusive.” We performed BAT using CD63 and CD203c as activation markers in patients and controls. Patients underwent DPT regardless of BAT results to prevent bias.ResultsST positivity significantly correlated with skin involvement, Type I phenotype, cancer recurrence, and lifetime exposures before reactions. DPTs were negative in all indeterminate phenotype patients (p = .02) and those considered low-risk, whereas they were negative in 62% moderate-risk patients. 55% were confirmed as hypersensitive (mainly Type I reactions, p < .0001), 24% as non-hypersensitive (mainly TXs and indeterminate phenotypes), and 21% as inconclusive. BAT showed 79% sensitivity in Type I IgE-mediated reactions to PSs with a high correlation to ST.
PB Wiley
YR 2024
FD 2024
LK https://hdl.handle.net/10630/32928
UL https://hdl.handle.net/10630/32928
LA eng
NO Bogas G, Ariza A, Vázquez-Revuelta P, et al. Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes. Allergy. 2024; 00: 1-16. doi:10.1111/all.16296
NO Funding for open access charge: Universidad de Málaga / CBUA. This work was supported by the Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO), grants co-founded by Fondo Europeo de Desarrollo Regional—FEDER for the Thematic Networks and Co-operative Research Centres: PI22/01119; PI18/00095; RETICS ARADYAL RD16/0006/0001, RICORS REI (RD21/0002/0008); Biobank network RD09/0076/00112; Biobank platform PT13/0010/0006; Andalusian Regional Ministry of Economy and Knowledge (grants PI-0076-2019). G.B. is a clinical investigator (B-0007-2022), research contract by Andalusian Regional Ministry Health. A.A. thanks Senior Postdoctoral Contract (RH-0099-2020) from Andalusian Regional Ministry of Health (co-funded by European Social Fund [ESF]: “Andalucía se mueve con Europa”) and “Nicolas Monardes” research contract by Andalusian Regional Ministry Health (C1-0007-2023). CLM holds a P-FIS contract (FI23/00027) by ISCIII. SCS holds a predoctoral contract by Andalusian Regional Goverment (PREDOC_01545). CM holds a “Nicolas Monardes” research contract by Andalusian Regional Ministry Health (RC-0004-2021).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026